GYEONGGI-PROVINCE
1.9.2021 10:02:11 CEST | Business Wire | Press release
With the volume and value of data increasing in line with the accelerated digital transformation, Gyeonggi Province will hold the world’s first ‘data sovereignty’ forum to discuss the ways of protecting and practicing individuals’ data rights.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210901005013/en/
According to Gyeonggi Province at the press conference on July 28th, the ‘Data Sovereignty International Forum 2021’ will be held on September 8 as a virtual event (DSIF2021.com ).
Together with overseas local governments, Gyeonggi Province hosts the Data Sovereignty International Forum under the slogan, ‘My Data, My Right’. The forum aims to further develop the province’s data sovereignty policy, which has been promoted since the execution of the world’s first data dividend payout in February last year, and to publicize individuals’ data sovereignty.
Gyeonggido Business & Science Accelerator and MyData Global, a private international organization, organize the event and the Presidential Committee on the Fourth Industrial Revolution, the Personal Information Protection Commission, Korea Internet & Security Agency, and Korea Data Agency will participate as sponsors. The sponsoring agencies will not only provide lectures and promotional services to improve and spread the data sovereignty awareness, but cooperate in Gyeonggi Province’s data sovereignty policy implementation after the forum.
As data have become an important value in the current society, ‘individuals’ data sovereignty’ will be discussed for the first time in the world under the subject of ‘Making a Fair Data World Together.’ Domestic and international data sovereignty and MyData experts, the related government agencies, and overseas private organizations will discuss the ways of and the users’ role in creating a fair data world with a focus on individual rights.
At the opening ceremony on September 8, Governor Lee Jaemyung of Gyeonggi Province will give an opening address followed by a keynote lecture by Sir Tim Berners-Lee, the inventor of the World Wide Web, titled ‘Transformation in the Digital World and Data Sovereignty.’
The keynote lecture that will last about 30 minutes can be watched only through real-time channels, such as the Digital Sovereignty International Forum website (DSIF2021.com ) and Gyeonggi Province’s YouTube channel (youtube.com/ggholics ).
Lim Mun-yeong, Director of Gyeonggi Province Future Growth Policy Division, said, “Data sovereignty holds an important value as it enables individuals to autonomously utilize data and benefit from using it. Gyeonggi Province invites you to take part in this event so that we can understand and practice data sovereignty, a natural right for all, and make the data world fairer.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20210901005013/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 15:00:00 CEST | Press release
New Washington State facility provides capacity to manufacture more than 30,000 radars annually, strengthening the U.S. defense industrial base As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructu
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 15:00:00 CEST | Press release
Analysis of more than 1,200 production cloud environments provides a first-hand view into how organizations are embedding AI into business-critical workflows, exposing new security risks that traditional controls weren't built to address. Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become ope
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 15:00:00 CEST | Press release
Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai's health system network Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's co
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9.7.2026 14:45:00 CEST | Press release
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.bus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom